Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | TLR2 | O60603 | 1/20 | 0.40 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | DHFR | P00374 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12589770 | 0.92 | TSHR (0.40) | MMP2NPC1TSHRKMT2ASMN1; SMN2 | |
| SCHEMBL2059262 | 0.83 | MMP2 (0.41) | MMP2TSHRKMT2ASMN1; SMN2RECQL | |
| SCHEMBL2059410 | 0.81 | LMNA (0.47) | NPC1TSHRKMT2ASMN1; SMN2MAPT | |
| SCHEMBL15719248 | 0.80 | MMP2 (0.47) | MMP2KMT2AGRIN2B | |
| SCHEMBL2059323 | 0.79 | MMP2 (0.41) | MMP2KMT2AMAPTMEN1DHFR | |
| SCHEMBL26529540 | 0.77 | ALDH1A1 (0.45) | MMP2TSHRPDE4B | |
| SCHEMBL12589774 | 0.77 | CYP2D6 (0.38) | MMP2TSHRKMT2ASMN1; SMN2RECQL | |
| SCHEMBL8132886 | 0.76 | KMT2A (0.60) | MMP2TSHRKMT2ASMN1; SMN2RECQL | |
| SCHEMBL10390327 | 0.76 | KMT2A (0.60) | MMP2TSHRKMT2ASMN1; SMN2RECQL | |
| SCHEMBL6196385 | 0.76 | KMT2A (0.60) | MMP2TSHRKMT2ASMN1; SMN2RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968733-B2 | Pyrrolidine analogue for preventing neurogenic pain and method for production thereof | GIFU UNIVERSITY (JP) | 2011-06-28 | — | — | US | disclosed |
| US-20090306407-A1 | Pyrrolidine analogue for preventing neurogenic pain and method for production thereof | GIFU UNIVERSITY (JP) | 2009-12-10 | — | — | US | disclosed |
| EP-2058301-A1 | PYRROLIDINE ANALOGUE FOR PREVENTING NEUROGENIC PAIN AND METHOD FOR PRODUCTION THEREOF | Gifu University (JP) | 2009-05-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306407-A1 | Pyrrolidine analogue for preventing neurogenic pain and method for production thereof | HNMT, OPRK1, OPRL1 | MMP2 1780/4885NPC1 2023/4885TSHR 4643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.